Rituximab or biosimilar

Phase 2

Sanofi

Rituximab or biosimilar is one of 8 therapeutic programs targeting Transplant. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

TransplantActive, not recruiting

TransplantPhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Transplant

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 2

1 2

Myfortic

Novartis

Phase 2

1 3

Prograf

VVeloxis Pharmaceuticals

Phase 2

1 4

Immunoglobulin

Sanofi

Phase 2

1 5

Antithymocyte Globulin

Sanofi

Phase 2

1 6

Intravenous Immunoglobulin

UUniversity of Alabama at Birmingham

Phase 2

1 7

BIVV020

Sanofi

Phase 2

1 8

Rituximab or biosimilar

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Transplant

NCT05156710

Clinical

Trials by Indication[1]

Transplant1 trial

A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT05156710·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rituximab or biosimilar. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Rituximab or biosimilar. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Sanofi

Rituximab or biosimilar

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Transplant1 trial

References

Drug Info

Quick Facts

Related News